Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other brokerages have also issued reports on APTO. HC Wainwright reissued a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. Piper Sandler reaffirmed an overweight rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group reduced their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $14.83.

Aptose Biosciences Stock Down 6.5 %

Shares of NASDAQ:APTO opened at $0.49 on Thursday. The firm has a fifty day moving average of $0.78 and a two-hundred day moving average of $1.30. The firm has a market capitalization of $8.86 million, a P/E ratio of -0.08 and a beta of 1.27. Aptose Biosciences has a 12-month low of $0.47 and a 12-month high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. Equities research analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.